Literature DB >> 10637526

Differential protective effect of bacillus Calmette-Guerin vaccine against multibacillary and paucibacillary leprosy in Nagpur, India.

H R Kulkarni1, S P Zodpey.   

Abstract

For this paper we conducted a secondary data analysis to test the hypothesis that a linear trend exists in the protective effect of bacillus Calmette-Guerin (BCG) vaccine against types of leprosy. We used data from two previous case-control studies to perform an unmatched test for linear trend. We observed that both the studies revealed a significant linear trend (P<0.00001). One study that estimated an insignificant protective effect of BCG against paucibacillary leprosy showed a significant departure from linearity. We conclude that, the protective effect of BCG vaccination is differential across severity of leprosy as it brings about a shift in the immune response to a higher level of cell mediated immunity. We recommend that future studies dealing with the protective effect of BCG against leprosy should also conduct an analysis for trend.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10637526     DOI: 10.1016/s0033-3506(99)00187-0

Source DB:  PubMed          Journal:  Public Health        ISSN: 0033-3506            Impact factor:   2.427


  2 in total

1.  Generation of CD8+ T-cell responses by a recombinant nonpathogenic Mycobacterium smegmatis vaccine vector expressing human immunodeficiency virus type 1 Env.

Authors:  Mark J Cayabyab; Avi-Hai Hovav; Tsungda Hsu; Georgia R Krivulka; Michelle A Lifton; Darci A Gorgone; Glenn J Fennelly; Barton F Haynes; William R Jacobs; Norman L Letvin
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

2.  Closely related mycobacterial strains demonstrate contrasting levels of efficacy as antitumor vaccines and are processed for major histocompatibility complex class I presentation by multiple routes in dendritic cells.

Authors:  Eleanor J Cheadle; Dearbhaile O'Donnell; Peter J Selby; Andrew M Jackson
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.